Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

NCT05257512 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SY-3505

Sponsor

Shouyao Holdings (Beijing) Co. LTD